Riboflavin: Clinical Trials

83 trials of Riboflavin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 completed, 24 unknown, 9 terminated, 6 withdrawn. 28 Phase 3, 27 Phase 2, 21 Not applicable, 8 Phase 1, 4 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 328Unknown 11, Completed 10, Terminated 4, Withdrawn 2, Recruiting 1
Phase 227Unknown 11, Completed 10, Withdrawn 3, Terminated 2, Recruiting 1
Not applicable21Completed 10, Unknown 4, Terminated 3, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1
Phase 18Completed 4, Unknown 3, Terminated 1
Early Phase 14Completed 2, Not yet recruiting 1, Unknown 1
Phase 44Completed 4

Follow Riboflavin: new trials by email Literature Review of Riboflavin trials Research Report on Riboflavin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
Vitamin C, Vitamin B2, Astragalus Root dry extract etc - Bioavailability and Pharmacokinetics
Not applicableNot yet recruitingSichuan Credit Pharmaceutical Co., Ltd.322026-06-012026-07-01
Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia
Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light - Keratoconus, Corneal Ectasia
Phase 2 / Phase 3RecruitingPrice Vision Group5002025-10-012026-09-25
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment - Keratoconus
Phase 3CompletedEpion Therapeutics3982023-11-012026-06-25
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment - Keratoconus
Phase 3CompletedEpion Therapeutics3962023-10-302026-06-25
Cytoflavin in the Complex Rehabilitation of Stroke Patients
Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Stroke
Phase 3CompletedPOLYSAN Scientific & Technological Pharmaceutical Company2402023-06-302026-04-14
Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes
Riboflavin, Placebo - Muscle Soreness
Early Phase 1CompletedSteven Moore1502023-06-232025-04-03
Pack Cross Linking for Infectious Keratitis
Riboflavin, Antibotice.g vigamox ED Antifungal e.g Dflucan, pack cross linking - Infectoius Keratitis
Not applicableUnknownSohag University602023-06-152023-05-31
Effect of Colon Delivered Vitamin B2 on Gut Microbiota and Related Health Biomarkers in Healthy Older Adults
Riboflavin - Quality of Life
Not applicableCompleteddsm-firmenich Switzerland AG3482022-12-122026-11-10
Intervention With Riboflavin to Improve Vascular Health and ENdothelial Functioning in Genetically at- Risk Adults
Placebo, Riboflavin 1.6mg/d, Riboflavin 5mg/d - Blood Pressure, Hypertension
Not applicableUnknownUniversity of Ulster1202022-09-012022-08-09
Cytoflavin in Combination With Reperfusion in Stroke Patients
Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control - Acute Stroke
CompletedPOLYSAN Scientific & Technological Pharmaceutical Company2002022-04-102023-03-20
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears - Keratitis, Corneal Ulcer
Phase 2 / Phase 3UnknownPeschke GmbH4882022-03-142022-10-28
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears - Keratitis, Corneal Ulcer
Phase 2 / Phase 3UnknownPeschke GmbH4682022-03-142022-10-28
Riboflavin for Glutamate Reduction in Alcohol Withdrawal
Riboflavin, Placebo - Alcohol Withdrawal, Nutrition Disorders
Phase 2UnknownOregon Health and Science University402021-12-012021-09-29
Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL)
Riboflavin - Keratoconus, Unstable
Early Phase 1Not yet recruitingKent Wellish MD6002021-06-302021-05-25
Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia
Riboflavin - Keratoconus, Corneal Ectasia
Phase 3UnknownCornea and Laser Eye Institute1602021-06-022023-01-04
Iron and Vitamin Supplementation in Hip/Knee Surgery
Iron plus folic acid, vitamin B2, B6, B12, C, and E - Orthopedic Disorder, Hip Arthropathy
Not applicableCompletedI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio602021-04-212023-05-06
Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose
Riboflavin - Keratoconus, Corneal Ectasia
Phase 3UnknownCornea and Laser Eye Institute1702021-04-162023-01-04
Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy
Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Diabetic Neuropathies
Phase 3CompletedPOLYSAN Scientific & Technological Pharmaceutical Company2162020-11-252023-01-27
International Trial of Efficacy of Cytoflavin in Head Trauma
Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), Placebo - Head Trauma,Closed
Phase 3CompletedPOLYSAN Scientific & Technological Pharmaceutical Company1662020-11-222025-04-18
Head Yuanshi Dian Therapy in Burning Mouth Syndrome
oryzanol + vitamin B2 (riboflavin) + vitamin E - Burning Mouth Syndrome, Oral Mucosa Disease
Early Phase 1UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine2902020-07-272021-07-19

Showing 20 of 83. Sign in to see all of them.

Conditions studied

Keratoconus (28)  ·  Dilatation, Pathologic (10)  ·  Corneal Diseases (5)  ·  Corneal Ulcer (4)  ·  Brain Concussion (3)  ·  HIV Infections (3)  ·  Acidosis, Lactic (2)  ·  Cognitive Dysfunction (2)  ·  Hypertension (2)  ·  Keratitis (2)  ·  Stroke (2)  ·  Abortion, Habitual (1)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Alcoholism (1)  ·  Anemia (1)

Sponsors

Cornea and Laser Eye Institute (5)  ·  POLYSAN Scientific & Technological Pharmaceutical Company (5)  ·  University of Ulster (4)  ·  Cxlusa (3)  ·  Price Vision Group (3)  ·  Topcon Medical Systems, Inc. (3)  ·  dsm-firmenich Switzerland AG (3)  ·  Epion Therapeutics (2)  ·  Joseph B. Ciolino, MD (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Peschke GmbH (2)  ·  Stephen Trokel (2)  ·  University of Missouri-Columbia (2)  ·  University of Virginia (2)  ·  Assistance Publique - Hôpitaux de Paris (1)

Countries

United States (44)  ·  United Kingdom (6)  ·  Russia (5)  ·  Canada (3)  ·  Ireland (3)  ·  Austria (2)  ·  Brazil (2)  ·  China (1)  ·  Egypt (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  India (1)  ·  Iran (1)  ·  Israel (1)

Top investigators

William Trattler, MD (3)  ·  Bala Ambati (2)  ·  Francis W Price, MD (2)  ·  Michael Belin, MD (2)  ·  Peter Hersh, MD (2)  ·  Peter S Hersh, MD (2)  ·  Stephen Trokel, MD (2)  ·  Steven A Greenstein, MD (2)  ·  Yvette Viscuso (2)  ·  Aimee McRae-Clark, PharmD, BCPP (1)  ·  Aleksandar Stojanovic, MD (1)  ·  Alexander V Savello, Prof (1)  ·  Alexey Shmonin, Prof (1)  ·  Belquiz A Nassaralla, MD, PhD (1)  ·  Bernard Cholley, MD, PhD (1)

Results publications

PMID 32557558, PMID 18471635, PMID 15076242, PMID 16765803, PMID 16952090, PMID 18811118, PMID 20138607, PMID 20164744, PMID 22741619, PMID 23062001, PMID 23929075, PMID 24507091, PMID 25938990, PMID 26997458, PMID 27418639, PMID 27496105, PMID 27899371, PMID 28325070, PMID 28787507, PMID 29203068, PMID 32532654, PMID 33615992, PMID 33779986, PMID 35680173, PMID 35943883, PMID 37343287, PMID 41551305

NIH funding

2017 (1), P01NS044233 (1), P50DA009236 (1), R01DA025074 (1), R21AG050850 (1), U54NS065736 (1)